Pinocembrin Crystalline Forms Bioavailability Uptake Rate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of pinocembrin lack specificity in drug uptake rates and bioavailability, affecting their efficacy in treating diseases such as cerebral ischemia due to the absence of distinct crystalline forms.
Innovation Solution
Development of two crystalline forms of pinocembrin, α and β, which differ in uptake rates and bioavailability, with the β form having a greater than two-fold higher uptake rate than the α form, and their use in pharmaceutical compositions to enhance treatment efficacy for cerebral ischemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pinocembrin pharmaceutical compositions are used, then the drug can be administered, but the uptake rate and bioavailability are insufficient and lack specificity
Solution Approach 1:
The patent applies parameter changes by discovering and utilizing different crystalline forms (polymorphs) of pinocembrin. The β crystalline form exhibits superior bioavailability and uptake rate compared to the α crystalline form, demonstrating how changing the physical state parameter (crystalline structure) of the same chemical compound can dramatically improve drug performance. This resolves the contradiction by providing a specific crystalline form parameter optimization that simultaneously enhances both reliability and productivity.
Solution Approach 2:
The patent applies local quality by identifying that different regions (crystalline forms) of the same pinocembrin compound have different properties. Specifically, the β crystalline form possesses localized superior characteristics in terms of bioavailability and uptake rate, while the α crystalline form has different properties. This allows selective use of the appropriate crystalline form for specific therapeutic needs, resolving the contradiction between reliability and productivity.
2Reliability
If a single crystalline form of pinocembrin is used, then the formulation is simple, but the treatment efficacy is limited due to insufficient bioavailability
Solution Approach 1:
The patent utilizes parameter changes by establishing different crystalline form specifications for pinocembrin. By defining specific crystalline forms (α and β) with distinct properties, the patent enables selection of the optimal form for maximum treatment efficacy. The β crystalline form is identified as having superior bioavailability, directly addressing the treatment efficacy requirement while maintaining manageable complexity through clear form specification.
3Productivity
If the β crystalline form is used to achieve high uptake rate, then the bioavailability improves, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies parameter changes by establishing controlled preparation conditions that yield the desired β crystalline form. By defining specific manufacturing parameters (solvent selection, temperature control, crystallization conditions), the patent makes it feasible to produce the high-performance β crystalline form without excessive manufacturing complexity. This resolves the contradiction by providing a reproducible method to achieve superior uptake rate while maintaining practical manufacturability.
Data Source
AI summary
Two crystalline forms of pinocembrin of formula (I): α and β, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in vivo.